Effects of excess iodine administration on thyroid function in euthyroid patients with a previous episode of thyroid dysfunction induced by interferon-alpha treatment

Roberta Minelli, Lewis E. Braverman, Tiziana Giuberti, Claudia Schianchi, Eliana Gardini, Mario Salvi, Franco Fiaccadori, Giorgio Ugolotti, Elio Roti

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: To determine the effects of pharmacological quantities of iodide (SSKI) on thyroid function in euthyroid patients previously treated with recombinant interferon-alpha (rIFN-α) for chronic vital hepatitis B and C (HCV), a cytokine which may induce thyroid dysfunction. DESIGN: Thyroid function tests were carried out in 16 euthyroid patients, 8 of whom had previously developed thyroid dysfunction during rIFN-α therapy for HCV, before, during and after the administration of 10 drops of saturated solution of potassium iodide (SSKI) (~350 mg iodide). PATIENTS: All 16 patients had been treated in the past with rIFN-α for HCV. Eight patients had developed rIFN-α induced abnormalities in thyroid function (5 inflammatory thyrotoxicosis, 1 Graves' disease, and 2 impaired thyroid organification of iodide) and 8 had not developed thyroid dysfunction. MEASUREMENTS: After baseline serum free T4 (FT4) and free T3 (FT3) concentrations, basal and TRH stimulated TSH concentrations, and TSH-receptor (TSH-R-Ab) and thyroid peroxidase (TPO-Ab) anti-bodies were measured, 10 drops saturated solution of potassium iodide (SSKI, ~350mg iodide) were given daily for 60 days and the above parameters assessed during and after SSKI was discontinued. RESULTS: Five of 8 patients with a previous history of rIFN-α induced thyroid dysfunction developed mild iodide induced abnormalities of thyroid function (subclinical hypothyroidism (slightly elevated basal and TRH stimulated serum TSH concentrations with normal serum FT4 and FT3 concentrations) or hyperthyroidism) compared with the 8 patients who had no previous evidence of thyroid dysfunction during rIFN-α therapy. CONCLUSIONS: In view of the present observations, it is prudent to avoid the administration of excess iodine to euthyroid subjects with a previous episode of thyroid dysfunction during rIFN-α therapy, adding a new group of patients susceptible to iodine induced thyroid disease.

Original languageEnglish
Pages (from-to)357-361
Number of pages5
JournalClinical Endocrinology
Volume47
Issue number3
Publication statusPublished - 1997

Fingerprint

Interferon-alpha
Iodine
Thyroid Gland
Potassium Iodide
Iodides
Therapeutics
Serum
Thyroid Function Tests
Thyrotropin Receptors
Iodide Peroxidase
Thyrotoxicosis
Graves Disease
Thyroid Diseases
Chronic Hepatitis B
Chronic Hepatitis C
Hyperthyroidism
Hypothyroidism
Pharmacology
Cytokines

ASJC Scopus subject areas

  • Endocrinology

Cite this

Effects of excess iodine administration on thyroid function in euthyroid patients with a previous episode of thyroid dysfunction induced by interferon-alpha treatment. / Minelli, Roberta; Braverman, Lewis E.; Giuberti, Tiziana; Schianchi, Claudia; Gardini, Eliana; Salvi, Mario; Fiaccadori, Franco; Ugolotti, Giorgio; Roti, Elio.

In: Clinical Endocrinology, Vol. 47, No. 3, 1997, p. 357-361.

Research output: Contribution to journalArticle

Minelli, R, Braverman, LE, Giuberti, T, Schianchi, C, Gardini, E, Salvi, M, Fiaccadori, F, Ugolotti, G & Roti, E 1997, 'Effects of excess iodine administration on thyroid function in euthyroid patients with a previous episode of thyroid dysfunction induced by interferon-alpha treatment', Clinical Endocrinology, vol. 47, no. 3, pp. 357-361.
Minelli, Roberta ; Braverman, Lewis E. ; Giuberti, Tiziana ; Schianchi, Claudia ; Gardini, Eliana ; Salvi, Mario ; Fiaccadori, Franco ; Ugolotti, Giorgio ; Roti, Elio. / Effects of excess iodine administration on thyroid function in euthyroid patients with a previous episode of thyroid dysfunction induced by interferon-alpha treatment. In: Clinical Endocrinology. 1997 ; Vol. 47, No. 3. pp. 357-361.
@article{39d79309e622460f9c1726cbee773924,
title = "Effects of excess iodine administration on thyroid function in euthyroid patients with a previous episode of thyroid dysfunction induced by interferon-alpha treatment",
abstract = "OBJECTIVE: To determine the effects of pharmacological quantities of iodide (SSKI) on thyroid function in euthyroid patients previously treated with recombinant interferon-alpha (rIFN-α) for chronic vital hepatitis B and C (HCV), a cytokine which may induce thyroid dysfunction. DESIGN: Thyroid function tests were carried out in 16 euthyroid patients, 8 of whom had previously developed thyroid dysfunction during rIFN-α therapy for HCV, before, during and after the administration of 10 drops of saturated solution of potassium iodide (SSKI) (~350 mg iodide). PATIENTS: All 16 patients had been treated in the past with rIFN-α for HCV. Eight patients had developed rIFN-α induced abnormalities in thyroid function (5 inflammatory thyrotoxicosis, 1 Graves' disease, and 2 impaired thyroid organification of iodide) and 8 had not developed thyroid dysfunction. MEASUREMENTS: After baseline serum free T4 (FT4) and free T3 (FT3) concentrations, basal and TRH stimulated TSH concentrations, and TSH-receptor (TSH-R-Ab) and thyroid peroxidase (TPO-Ab) anti-bodies were measured, 10 drops saturated solution of potassium iodide (SSKI, ~350mg iodide) were given daily for 60 days and the above parameters assessed during and after SSKI was discontinued. RESULTS: Five of 8 patients with a previous history of rIFN-α induced thyroid dysfunction developed mild iodide induced abnormalities of thyroid function (subclinical hypothyroidism (slightly elevated basal and TRH stimulated serum TSH concentrations with normal serum FT4 and FT3 concentrations) or hyperthyroidism) compared with the 8 patients who had no previous evidence of thyroid dysfunction during rIFN-α therapy. CONCLUSIONS: In view of the present observations, it is prudent to avoid the administration of excess iodine to euthyroid subjects with a previous episode of thyroid dysfunction during rIFN-α therapy, adding a new group of patients susceptible to iodine induced thyroid disease.",
author = "Roberta Minelli and Braverman, {Lewis E.} and Tiziana Giuberti and Claudia Schianchi and Eliana Gardini and Mario Salvi and Franco Fiaccadori and Giorgio Ugolotti and Elio Roti",
year = "1997",
language = "English",
volume = "47",
pages = "357--361",
journal = "Clinical Endocrinology",
issn = "0300-0664",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Effects of excess iodine administration on thyroid function in euthyroid patients with a previous episode of thyroid dysfunction induced by interferon-alpha treatment

AU - Minelli, Roberta

AU - Braverman, Lewis E.

AU - Giuberti, Tiziana

AU - Schianchi, Claudia

AU - Gardini, Eliana

AU - Salvi, Mario

AU - Fiaccadori, Franco

AU - Ugolotti, Giorgio

AU - Roti, Elio

PY - 1997

Y1 - 1997

N2 - OBJECTIVE: To determine the effects of pharmacological quantities of iodide (SSKI) on thyroid function in euthyroid patients previously treated with recombinant interferon-alpha (rIFN-α) for chronic vital hepatitis B and C (HCV), a cytokine which may induce thyroid dysfunction. DESIGN: Thyroid function tests were carried out in 16 euthyroid patients, 8 of whom had previously developed thyroid dysfunction during rIFN-α therapy for HCV, before, during and after the administration of 10 drops of saturated solution of potassium iodide (SSKI) (~350 mg iodide). PATIENTS: All 16 patients had been treated in the past with rIFN-α for HCV. Eight patients had developed rIFN-α induced abnormalities in thyroid function (5 inflammatory thyrotoxicosis, 1 Graves' disease, and 2 impaired thyroid organification of iodide) and 8 had not developed thyroid dysfunction. MEASUREMENTS: After baseline serum free T4 (FT4) and free T3 (FT3) concentrations, basal and TRH stimulated TSH concentrations, and TSH-receptor (TSH-R-Ab) and thyroid peroxidase (TPO-Ab) anti-bodies were measured, 10 drops saturated solution of potassium iodide (SSKI, ~350mg iodide) were given daily for 60 days and the above parameters assessed during and after SSKI was discontinued. RESULTS: Five of 8 patients with a previous history of rIFN-α induced thyroid dysfunction developed mild iodide induced abnormalities of thyroid function (subclinical hypothyroidism (slightly elevated basal and TRH stimulated serum TSH concentrations with normal serum FT4 and FT3 concentrations) or hyperthyroidism) compared with the 8 patients who had no previous evidence of thyroid dysfunction during rIFN-α therapy. CONCLUSIONS: In view of the present observations, it is prudent to avoid the administration of excess iodine to euthyroid subjects with a previous episode of thyroid dysfunction during rIFN-α therapy, adding a new group of patients susceptible to iodine induced thyroid disease.

AB - OBJECTIVE: To determine the effects of pharmacological quantities of iodide (SSKI) on thyroid function in euthyroid patients previously treated with recombinant interferon-alpha (rIFN-α) for chronic vital hepatitis B and C (HCV), a cytokine which may induce thyroid dysfunction. DESIGN: Thyroid function tests were carried out in 16 euthyroid patients, 8 of whom had previously developed thyroid dysfunction during rIFN-α therapy for HCV, before, during and after the administration of 10 drops of saturated solution of potassium iodide (SSKI) (~350 mg iodide). PATIENTS: All 16 patients had been treated in the past with rIFN-α for HCV. Eight patients had developed rIFN-α induced abnormalities in thyroid function (5 inflammatory thyrotoxicosis, 1 Graves' disease, and 2 impaired thyroid organification of iodide) and 8 had not developed thyroid dysfunction. MEASUREMENTS: After baseline serum free T4 (FT4) and free T3 (FT3) concentrations, basal and TRH stimulated TSH concentrations, and TSH-receptor (TSH-R-Ab) and thyroid peroxidase (TPO-Ab) anti-bodies were measured, 10 drops saturated solution of potassium iodide (SSKI, ~350mg iodide) were given daily for 60 days and the above parameters assessed during and after SSKI was discontinued. RESULTS: Five of 8 patients with a previous history of rIFN-α induced thyroid dysfunction developed mild iodide induced abnormalities of thyroid function (subclinical hypothyroidism (slightly elevated basal and TRH stimulated serum TSH concentrations with normal serum FT4 and FT3 concentrations) or hyperthyroidism) compared with the 8 patients who had no previous evidence of thyroid dysfunction during rIFN-α therapy. CONCLUSIONS: In view of the present observations, it is prudent to avoid the administration of excess iodine to euthyroid subjects with a previous episode of thyroid dysfunction during rIFN-α therapy, adding a new group of patients susceptible to iodine induced thyroid disease.

UR - http://www.scopus.com/inward/record.url?scp=0030827008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030827008&partnerID=8YFLogxK

M3 - Article

C2 - 9373459

AN - SCOPUS:0030827008

VL - 47

SP - 357

EP - 361

JO - Clinical Endocrinology

JF - Clinical Endocrinology

SN - 0300-0664

IS - 3

ER -